Blue Spark Technologies, a digital health company specializing in AI-powered remote patient monitoring (RPM) to support precision drug development, has appointed MaryAnne Rizk, Ph.D., a leader in drug development technological innovation, to its advisory board.
Dr. Rizk will work with Blue Spark Technologies to identify areas for integrated growth and innovation in RPM and real-world data (RWD). Dr. Rizk brings more than 20 years of experience to the board. She has worked with CVS, Merck, Medidata, Oracle, IQVIA and Medable with domain expertise in AI/ML, RWD, RPM, Precision Medicine and Decentralized Clinical Trials (DCT).
Blue Spark Technologies is focused on precision monitoring of patient vital signs. Their flagship product, TempTraq, is an FDA-cleared disposable monitor that continuously measures and records core body temperature every 10 seconds.
“We are incredibly fortunate to welcome Dr. Rizk to our advisory board,” said John Gannon, President and CEO of Blue Spark Technologies. “Her remarkable track record and profound knowledge in digital health will be invaluable as we continue to be at the forefront of redefining patient monitoring standards. I am confident that the collective expertise of our board will further propel Blue Spark Technologies to new heights of success.”
“I am thrilled to be appointed to the Board of Advisors for Blue Spark Technologies,” said Dr. Rizk. “Blue Spark Technologies is a vanguard in digital health technology that improves patient safety. This reinforces my personal commitment to revolutionize patient care through intelligent precision monitoring innovation. I am eager to add my insights to their work, sculpt the industry’s future and collaborate with Blue Spark’s talented team. I aim to implement impactful strategies and support the company’s growth trajectory.”